Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo
Bisphosphonates (such as risedronate and zoledronate) are widely used inhibitors of bone resorption. Despite their in vitro antiproliferative effects in various cancer cells, bisphosphonates have not exhibited significant antitumor efficacy in animal models of visceral cancer, which may be due to th...
Saved in:
| Published in: | Clinical cancer research Vol. 12; no. 9; p. 2862 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.05.2006
|
| Subjects: | |
| ISSN: | 1078-0432 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Bisphosphonates (such as risedronate and zoledronate) are widely used inhibitors of bone resorption. Despite their in vitro antiproliferative effects in various cancer cells, bisphosphonates have not exhibited significant antitumor efficacy in animal models of visceral cancer, which may be due to their poor bioavailability. The diagnostic use of radioactive bisphosphonates has revealed the accumulation of bisphosphonates in mesothelioma, which prompted us to test the antitumor efficacy of bisphosphonates in this disease.
Treatment with either risedronate or zoledronate (2 x 10(-4) to 2 x 10(-6) mol/L) inhibited the growth of AB12 and AC29 mouse mesothelioma cells and induced the accumulation of unprenylated Rap1A in these cells. Both these in vitro effects were reversed by geranygeraniol, an end product of the mevalonate pathway that these bisphosphonates inhibit. Both bisphosphonates also induced the phosphorylation of the p38 mitogen-activated protein kinase in AB12 and AC29 cells. The inhibition of p38 augmented bisphosphonate-induced growth inhibition in these cells. Bisphosphonate-induced p38 phosphorylation was not reversible by geranylgeraniol. Risedronate (15 mg/kg) and zoledronate (0.5 mg/kg) inhibited the growth of s.c. tumors and increased the median survival of mice with i.p. mesothelioma tumors in vivo.
In conclusion, risedronate and zoledronate inhibit the mevalonate pathway and induce p38 activation in mesothelioma cells in vitro. The effects on the mevalonate pathway dominate because the net result is growth inhibition. Both bisphosphonates also inhibit mesothelioma tumor growth in vivo and prolong the survival of mesothelioma-bearing mice. These results support further study of bisphosphonates in the management of mesothelioma. |
|---|---|
| AbstractList | Bisphosphonates (such as risedronate and zoledronate) are widely used inhibitors of bone resorption. Despite their in vitro antiproliferative effects in various cancer cells, bisphosphonates have not exhibited significant antitumor efficacy in animal models of visceral cancer, which may be due to their poor bioavailability. The diagnostic use of radioactive bisphosphonates has revealed the accumulation of bisphosphonates in mesothelioma, which prompted us to test the antitumor efficacy of bisphosphonates in this disease.
Treatment with either risedronate or zoledronate (2 x 10(-4) to 2 x 10(-6) mol/L) inhibited the growth of AB12 and AC29 mouse mesothelioma cells and induced the accumulation of unprenylated Rap1A in these cells. Both these in vitro effects were reversed by geranygeraniol, an end product of the mevalonate pathway that these bisphosphonates inhibit. Both bisphosphonates also induced the phosphorylation of the p38 mitogen-activated protein kinase in AB12 and AC29 cells. The inhibition of p38 augmented bisphosphonate-induced growth inhibition in these cells. Bisphosphonate-induced p38 phosphorylation was not reversible by geranylgeraniol. Risedronate (15 mg/kg) and zoledronate (0.5 mg/kg) inhibited the growth of s.c. tumors and increased the median survival of mice with i.p. mesothelioma tumors in vivo.
In conclusion, risedronate and zoledronate inhibit the mevalonate pathway and induce p38 activation in mesothelioma cells in vitro. The effects on the mevalonate pathway dominate because the net result is growth inhibition. Both bisphosphonates also inhibit mesothelioma tumor growth in vivo and prolong the survival of mesothelioma-bearing mice. These results support further study of bisphosphonates in the management of mesothelioma. Bisphosphonates (such as risedronate and zoledronate) are widely used inhibitors of bone resorption. Despite their in vitro antiproliferative effects in various cancer cells, bisphosphonates have not exhibited significant antitumor efficacy in animal models of visceral cancer, which may be due to their poor bioavailability. The diagnostic use of radioactive bisphosphonates has revealed the accumulation of bisphosphonates in mesothelioma, which prompted us to test the antitumor efficacy of bisphosphonates in this disease.PURPOSEBisphosphonates (such as risedronate and zoledronate) are widely used inhibitors of bone resorption. Despite their in vitro antiproliferative effects in various cancer cells, bisphosphonates have not exhibited significant antitumor efficacy in animal models of visceral cancer, which may be due to their poor bioavailability. The diagnostic use of radioactive bisphosphonates has revealed the accumulation of bisphosphonates in mesothelioma, which prompted us to test the antitumor efficacy of bisphosphonates in this disease.Treatment with either risedronate or zoledronate (2 x 10(-4) to 2 x 10(-6) mol/L) inhibited the growth of AB12 and AC29 mouse mesothelioma cells and induced the accumulation of unprenylated Rap1A in these cells. Both these in vitro effects were reversed by geranygeraniol, an end product of the mevalonate pathway that these bisphosphonates inhibit. Both bisphosphonates also induced the phosphorylation of the p38 mitogen-activated protein kinase in AB12 and AC29 cells. The inhibition of p38 augmented bisphosphonate-induced growth inhibition in these cells. Bisphosphonate-induced p38 phosphorylation was not reversible by geranylgeraniol. Risedronate (15 mg/kg) and zoledronate (0.5 mg/kg) inhibited the growth of s.c. tumors and increased the median survival of mice with i.p. mesothelioma tumors in vivo.EXPERIMENTAL DESIGN AND RESULTSTreatment with either risedronate or zoledronate (2 x 10(-4) to 2 x 10(-6) mol/L) inhibited the growth of AB12 and AC29 mouse mesothelioma cells and induced the accumulation of unprenylated Rap1A in these cells. Both these in vitro effects were reversed by geranygeraniol, an end product of the mevalonate pathway that these bisphosphonates inhibit. Both bisphosphonates also induced the phosphorylation of the p38 mitogen-activated protein kinase in AB12 and AC29 cells. The inhibition of p38 augmented bisphosphonate-induced growth inhibition in these cells. Bisphosphonate-induced p38 phosphorylation was not reversible by geranylgeraniol. Risedronate (15 mg/kg) and zoledronate (0.5 mg/kg) inhibited the growth of s.c. tumors and increased the median survival of mice with i.p. mesothelioma tumors in vivo.In conclusion, risedronate and zoledronate inhibit the mevalonate pathway and induce p38 activation in mesothelioma cells in vitro. The effects on the mevalonate pathway dominate because the net result is growth inhibition. Both bisphosphonates also inhibit mesothelioma tumor growth in vivo and prolong the survival of mesothelioma-bearing mice. These results support further study of bisphosphonates in the management of mesothelioma.DISCUSSIONIn conclusion, risedronate and zoledronate inhibit the mevalonate pathway and induce p38 activation in mesothelioma cells in vitro. The effects on the mevalonate pathway dominate because the net result is growth inhibition. Both bisphosphonates also inhibit mesothelioma tumor growth in vivo and prolong the survival of mesothelioma-bearing mice. These results support further study of bisphosphonates in the management of mesothelioma. |
| Author | Wakchoure, Savita Aldrich, Wayne Harris, Kevin W Triozzi, Pierre Merrell, Melinda A Selander, Katri S Millender-Swain, Telisha |
| Author_xml | – sequence: 1 givenname: Savita surname: Wakchoure fullname: Wakchoure, Savita organization: Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35294-3300, USA – sequence: 2 givenname: Melinda A surname: Merrell fullname: Merrell, Melinda A – sequence: 3 givenname: Wayne surname: Aldrich fullname: Aldrich, Wayne – sequence: 4 givenname: Telisha surname: Millender-Swain fullname: Millender-Swain, Telisha – sequence: 5 givenname: Kevin W surname: Harris fullname: Harris, Kevin W – sequence: 6 givenname: Pierre surname: Triozzi fullname: Triozzi, Pierre – sequence: 7 givenname: Katri S surname: Selander fullname: Selander, Katri S |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16675582$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kMtOwzAQRb0oog_4BJBX7FI8tmM7S6goIBWxgXXkJDYxSuIQO0X8PY1aWIyu5uhoNLpLNOt8ZxC6ArIGSNUtEKkSwhldl-WQkDShUogZWvzzOVqG8EkIcCD8HM1BCJmmii7Qy70Lfe2n6XQ0AbuudoWLONYGfwz-O9bYW9ya4A-kcb7VuDRNM4l47-Lgse6q47L3F-jM6iaYy1Ou0Pv24W3zlOxeH583d7uk5IrFBHilRCoMsxlVVgkgQheUUM0l5yArpSUnUEqQBbGZpQwyRqkhRQnMFhmlK3RzvNsP_ms0IeatC9NbujN-DLmQGUuVUAfx-iSORWuqvB9cq4ef_K8A-gtgyV2t |
| CitedBy_id | crossref_primary_10_1183_16000617_0098_2017 crossref_primary_10_1038_s41598_022_25755_5 crossref_primary_10_1586_era_11_13 crossref_primary_10_1097_01_COT_0000383778_58160_53 crossref_primary_10_1186_s13063_018_2851_9 crossref_primary_10_1007_s10585_015_9727_0 crossref_primary_10_1007_s00232_016_9895_0 crossref_primary_10_1097_JTO_0b013e31824c7d43 crossref_primary_10_1158_1078_0432_CCR_14_2279 crossref_primary_10_3109_07357907_2010_512598 crossref_primary_10_1016_j_ijrobp_2025_03_059 crossref_primary_10_1039_D4RA07782B crossref_primary_10_3390_ijms26114990 crossref_primary_10_3892_ol_2019_10438 crossref_primary_10_1007_s10549_015_3624_8 crossref_primary_10_1164_rccm_200804_616ED crossref_primary_10_1097_SPC_0b013e328349dc17 crossref_primary_10_1016_j_bbcan_2025_189267 crossref_primary_10_1016_j_ica_2012_06_005 crossref_primary_10_1016_j_drup_2016_02_001 crossref_primary_10_1186_1471_2407_8_81 crossref_primary_10_1371_journal_pone_0004685 crossref_primary_10_1016_j_clinbiochem_2007_03_016 crossref_primary_10_1016_j_ejphar_2006_11_064 crossref_primary_10_1016_j_ejphar_2007_05_075 crossref_primary_10_1016_j_lungcan_2010_12_003 crossref_primary_10_1007_s12094_011_0634_9 crossref_primary_10_1016_j_jinorgbio_2010_12_011 crossref_primary_10_1158_1078_0432_CCR_06_0843 crossref_primary_10_1016_j_canlet_2010_02_008 crossref_primary_10_1016_j_canlet_2007_07_007 crossref_primary_10_1016_j_jpainsymman_2007_10_005 crossref_primary_10_1371_journal_pone_0118569 crossref_primary_10_3390_biom11091272 crossref_primary_10_1002_pros_20562 crossref_primary_10_3760_cma_j_issn_0366_6999_20122385 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1078-0432.ccr-05-2766 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 16675582 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: 5P30CA13148 |
| GroupedDBID | --- .55 .GJ 18M 29B 2FS 2WC 34G 39C 3O- 4H- 53G 5GY 5RE 5VS 6J9 ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW AENEX AFFNX AFHIN AFOSN AFRAH AFUMD AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 H~9 IH2 KQ8 L7B LSO MVM NPM OHT OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 UDS VH1 VXZ W2D W8F WHG WOQ X7M XJT YKV ZCG ZGI 7X8 AAFWJ AAJMC AETEA |
| ID | FETCH-LOGICAL-c483t-14d8656e3f928f86106ab202a474417d8a7401c717b0f9f2319322e0bc13fb922 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 46 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000237441900028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1078-0432 |
| IngestDate | Thu Sep 04 14:40:52 EDT 2025 Wed Feb 19 01:53:59 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c483t-14d8656e3f928f86106ab202a474417d8a7401c717b0f9f2319322e0bc13fb922 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://aacrjournals.org/clincancerres/article-pdf/12/9/2862/1968659/2862.pdf |
| PMID | 16675582 |
| PQID | 67935868 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_67935868 pubmed_primary_16675582 |
| PublicationCentury | 2000 |
| PublicationDate | 2006-05-01 |
| PublicationDateYYYYMMDD | 2006-05-01 |
| PublicationDate_xml | – month: 05 year: 2006 text: 2006-05-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2006 |
| SSID | ssj0014104 |
| Score | 2.0590525 |
| Snippet | Bisphosphonates (such as risedronate and zoledronate) are widely used inhibitors of bone resorption. Despite their in vitro antiproliferative effects in... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2862 |
| SubjectTerms | Animals Cell Division - drug effects Cell Line, Tumor Diphosphonates - pharmacology Diphosphonates - therapeutic use Disease Models, Animal Etidronic Acid - analogs & derivatives Etidronic Acid - therapeutic use Imidazoles - therapeutic use Mesothelioma - drug therapy Mesothelioma - pathology Mice Phosphorylation Risedronate Sodium |
| Title | Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/16675582 https://www.proquest.com/docview/67935868 |
| Volume | 12 |
| WOSCitedRecordID | wos000237441900028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB6qFfHivtR1Dl7HNpM0mYAgWixeWooo9BYms9iATWoT-_t9L4teBA8eEsiQhOHx8vK99SPkWklfA9D1mQJ4zLyAu0yA2WNB3Ne652lXBbYkmwjGYzGdhpMWuW16YbCssrGJpaHWmcIYedcPMGPni7vFB0POKMyt1gQaa6TtApDBgq5g-pND8JySPBD8G8Fw8Fzdv-P0Rfd77WYweMZcMG_GJP6KMct_zXDnf7vcJds1xqT3lVLskZZJ98nmqM6iH5DRQ5IvZhkeKUJNmqSzJE4KCmCQvoFfXsxoZunc5Nie9Z5kc0kxwI830lVSLDMqU11drLJD8jp8fBk8sZpWgSlPuAVzPC0AxRnXhlxYAfjJlzHvcekFyEemhUSWPgV-XtyzoQUACBiPm16sHNfGIedHZD3NUnNCKDhrABliq3HKnK9lLLWjlBUGXi7AV-mQq0ZMEagtblWmJvvMo0ZQHXJcSTpaVNM1IscHH6Yv-Omfz56RrSogguWH56Rt4YM1F2RDrYokX16W2gDn8WT0BYMMvU4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bisphosphonates+inhibit+the+growth+of+mesothelioma+cells+in+vitro+and+in+vivo&rft.jtitle=Clinical+cancer+research&rft.au=Wakchoure%2C+Savita&rft.au=Merrell%2C+Melinda+A&rft.au=Aldrich%2C+Wayne&rft.au=Millender-Swain%2C+Telisha&rft.date=2006-05-01&rft.issn=1078-0432&rft.volume=12&rft.issue=9&rft.spage=2862&rft_id=info:doi/10.1158%2F1078-0432.ccr-05-2766&rft_id=info%3Apmid%2F16675582&rft_id=info%3Apmid%2F16675582&rft.externalDocID=16675582 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |